Fangzhou's AI-Powered Chronic Care Model Named To Fortune China's Best Designs 2026
Fangzhou's AI-Powered Chronic Care Model Named to Fortune China's Best Designs 2026
Now in its fifth year, Fortune China's Best Designs list evaluates projects across innovation, real-world implementation, industry value, and broader social impact. The 2026 list places a particular focus on artificial intelligence, recognizing projects that apply innovation to address industry challenges while demonstrating commercial potential and social value. Fangzhou's inclusion highlights the practicality, scalability, and commercial viability of its AI-powered chronic care model.
Chronic disease management remains a critical pillar of China's public healthcare system, yet traditional models face persistent challenges, including fragmented services, high labor costs, inconsistent patient follow-ups, and limited personalization. To address these structural constraints and long-term care needs, Fangzhou began exploring AI applications in healthcare as early as 2022.
In 2025, powered by its proprietary“XingShi” Large Language Model (XS LLM), the Company launched its“AI + Chronic Care” service model. By embedding AI functionality across the entire patient journey-including health monitoring, medication guidance, follow-up management, and health education-the platform connects fragmented services into a more seamless and personalized care experience.
As the Company scaled its deployment of XS LLM in 2026, the model delivered tangible benefits across both patient and physician workflows:
- Workflow Optimization: Streamlines service delivery across both physician and patient touchpoints by automating routine tasks and processes to enhance operational efficiency
Enhanced Care Quality & Patient Adherence: Integrates professional clinical guidance into everyday health management, empowering individuals to build healthier routines and manage chronic conditions more effectively
This recognition from Fortune China marks another milestone in Fangzhou's strategic evolution into a“full-lifecycle personal health service partner.” Looking ahead, the Company will continue to integrate AI technology across broader healthcare scenarios, advancing the scaled deployment of new capabilities to drive industry-wide efficiency and support the long-term development of digital healthcare.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China's leading online chronic disease management platform, serving 59.8 million registered users and 282,000 physicians (as of June 30, 2026). The Company specializes in delivering tailored medical care and AI‐enabled precision medicine solutions. For more information, visit .
Media Contact
For further inquiries or interview requests, please contact:
Xingwei Zhao
Director of Public Relations
Email: ...
Disclaimer: This press release contains forward‐looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.
A photo accompanying this announcement is available at
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment